Skip to main content
Donate
Login
IASLC's 50th Anniversary
IASLC's 50th Anniversary
History
Support The Mission
Support The Mission
Partners for Thoracic Cancer Care
Legacy Society
IASLC Global Member Survey on Inclusivity
About Us
About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Careers
Contact
Search
Donate
Login
Conferences & Webinars
Conferences & Webinars
Upcoming Conferences & Webinars
Past Conferences & Webinars
WCLC 2024
Research & Education
Research & Education
Publications, Resources & Guidelines
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Lung Cancer 360
Research Projects
Research Projects
Staging Project
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Early-Career Opportunities
News
News
ILCN
Press Releases
Lung Cancer Considered Podcast
Membership
Membership
Become a Member
Renew Your Membership
Partner Society Membership Offers
Patient Advocacy
Patient Advocacy
STARS
Advocacy Partner Spotlight
Lung Cancer Awareness Month 2023 Highlights
Foundation
Foundation
Donor Recognition
Research Grant Program
Grant Recipient Spotlights
Research Grant Recipients
Search
Fulltext search
Fulltext search
Search
Displaying 73 - 84 items out of 121 results
ILCN article
Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs
ILCN article
Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?
ILCN article
Mutation or Amplification: Who MET the Expectations?
ILCN article
RET Therapy for NSCLC, a New Generation of Inhibitors
ILCN article
The Multitude of Options for First-Line Therapy for EGFR-Mutated Lung Cancer
ILCN article
The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy
ILCN article
Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice
ILCN article
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
ILCN article
Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
ILCN article
Insight Into Genomic Correlates of PD-L1 Expression and the Response to Immune Checkpoint Blockade
ILCN article
Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations
ILCN article
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC
Pagination
First
First page
‹
Previous page
…
3
4
5
6
7
8
9
10
11
›
Next page
Last
Last page